Exagen Q1 Earnings Call Highlights Exagen (
NASDAQ:XGN ) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
The autoimmune diagnostics
Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading Exagen Inc (XGN) beats Q2 2025 revenue estimates with $17.2M but posts wider loss. Stock jumps 6.77% pre-market as investors focus on growth potential.
Top movers in Thursday's pre-market session As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Get insights into the top gainers and losers of Wednesday's after-hours session. Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Tuesday's session: top gainers and losers Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Market Mayhem Winners: What Stocks Are Up Today? What stocks are up today? It’s a natural question following the implosion of the global markets and the answer might surprise you.
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 XGN stock results show that Exagen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 XGN stock results show that Exagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 XGN stock results show that Exagen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
